0.909
-0.02 (-2.38%)
Previous Close | 0.931 |
Open | 0.901 |
Volume | 238,364 |
Avg. Volume (3M) | 215,316 |
Market Cap | 16,011,239 |
Price / Sales | 317.95 |
Price / Book | 36.58 |
52 Weeks Range | |
Earnings Date | 14 Apr 2025 - 27 Apr 2025 |
Operating Margin (TTM) | -40,707.69% |
Diluted EPS (TTM) | -1.34 |
Quarterly Revenue Growth (YOY) | 180.00% |
Total Debt/Equity (MRQ) | 243.10% |
Current Ratio (MRQ) | 0.800 |
Operating Cash Flow (TTM) | -9.56 M |
Levered Free Cash Flow (TTM) | -4.40 M |
Return on Assets (TTM) | -326.50% |
Return on Equity (TTM) | -6,342.03% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | BioSig Technologies, Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | -0.5 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | -1.25 |
BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare’s biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Value |
% Held by Insiders | 30.77% |
Ownership
Name | Date | Shares Held |
---|---|---|
Cornerstone Planning Group Llc | 31 Dec 2024 | 5,000 |
Riverview Trust Co | 31 Dec 2024 | 60 |
Steward Partners Investment Advisory, Llc | 31 Dec 2024 | 50 |
Robbins Farley | 31 Dec 2024 | 8 |
52 Weeks Range | ||
Median | 2.75 (202.60%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Ascendiant Capital | 05 Dec 2024 | 2.75 (202.60%) | Buy | 1.47 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |